Retatrutide Dosage for Adults: Starting Dose, Titration & Max Dose

Direct answer: Adults begin retatrutide at 2mg once weekly and titrate every 4 weeks — 2mg → 4mg → 8mg → 12mg. Most adults reach a therapeutic maintenance dose of 8mg or 12mg by week 13. Age, baseline GI sensitivity, and comorbidities all influence the pace of escalation; older adults and those with GI conditions often benefit from a slower ramp.

Retatrutide's dosing schedule looks simple on paper — 2mg, 4mg, 8mg, 12mg. What the tables don't show is why the timing matters for adults specifically, what to do when side effects appear, and the key decision point most guides skip: whether 8mg is enough or you should push to 12mg. That is what this guide covers.

Retatrutide Dosage for Adults Chart

The table below is the adult dosing chart derived from the phase 2 trial that established retatrutide's dose range. Weekly dose, expected experience, and escalation criteria are all included.

Source: retatrutide phase 2 obesity trial, NCT04881760, reported in Jastreboff et al., NEJM 2023. Individual protocols may vary.

For a printable version of this chart, see our Retatrutide Dosage Chart.

Where These Dose Numbers Come From

Every dose on this page traces to a single study: NCT04881760, the phase 2 obesity trial published as Jastreboff et al., NEJM 2023. It randomized 338 adults aged 18–75 with a BMI between 30 and 50, or 27 to under 30 with a weight-related condition, and ran for 48 weeks. Participants with type 1 or type 2 diabetes were excluded. Seven groups:

Two things follow from that list, and between them they explain most of what this page recommends.

2mg → 4mg → 8mg → 12mg is not a convention someone invented. It is the literal escalation path of the 12mg arm — the only arm that ever reached 12mg. Nothing above 12mg once weekly has been given to a human in a published retatrutide trial.

The trial treated the starting dose as a variable in its own right. Arms beginning at 2mg and arms beginning at 4mg were run in parallel at both the 4mg and the 8mg target. Gastrointestinal side effects came out dose-related and, in the investigators' words, "partially mitigated with a lower starting dose (2 mg vs. 4 mg)". The 4mg and 8mg results were then reported pooled across both starting doses. That finding is the entire evidence base for starting low, and it is why 2mg rather than 4mg is the default.

The once-weekly interval comes from a separate phase 1 study, where retatrutide's half-life measured approximately 6 days and its pharmacokinetics were dose-proportional across the range tested.

One naming note worth having straight: TRIUMPH is the name of Lilly's phase 3 program — TRIUMPH-1 through TRIUMPH-9, covering obesity, type 2 diabetes, cardiovascular disease and knee osteoarthritis. Those trials register their arms only as "Dose 1" and "Dose 2"; the milligram levels behind those labels have never been disclosed, and as of August 2026 no phase 3 retatrutide results had been posted to ClinicalTrials.gov. Any chart claiming to reproduce a phase 3 titration schedule is guessing. The phase 2 arms above are the real numbers.

Why Adult Dosing Differs From Trial Averages

The phase 2 cohort was adults aged 18–75 with a BMI of 30 to 50, or 27 to under 30 with a weight-related comorbidity, and it excluded anyone with diabetes. The standard 4-week escalation schedule was validated in that population. In practice, however, adult patients vary considerably in how quickly they tolerate dose increases.

The Half-Life That Makes Once-Weekly Dosing Work

Retatrutide's half-life is approximately 6 days. Steady state — the point where blood levels stop fluctuating meaningfully between doses — takes about 4–5 weeks at any given dose level. Two practical consequences follow:

1. Tolerability cannot be fully assessed until week 3–4 at each dose. Side effects in week 1 are not reliably predictive of week 3 at the same dose.
2. The 4-week escalation window is calibrated, not arbitrary. It allows pharmacokinetics to stabilize before adding more compound.

Adults who rush titration tend to feel worse and are more likely to discontinue. Adults who follow the 4-week schedule report smoother experiences in clinical and community settings alike.

Age-Related Considerations for Adult Titration

Older adults (roughly 60+) and adults with reduced renal or hepatic function are not excluded from retatrutide protocols, but several practical adjustments apply:

• Slower escalation pace: Holding each dose level for 6–8 weeks instead of 4 is a reasonable conservative approach. There is no clinical penalty for a slower ramp.
• Lower maintenance target: Some older adults find 8mg is the appropriate ceiling given tolerability — the efficacy difference between 8mg and 12mg (22.8% vs 24.2% weight loss at 48 weeks) is small enough that it is easily outweighed by individual side effect burden.
• Hydration and GI sensitivity: Older adults are at higher risk of dehydration from GI side effects. Proactive hydration management during the escalation phase is more important in this group.
• Medication interactions: GLP-1 receptor activation slows gastric emptying, which can affect absorption timing of oral medications. Confirm timing of any critical oral drugs with a prescriber before starting.

None of this requires a fundamentally different protocol — the 2mg → 4mg → 8mg → 12mg framework remains the same. The pace and the ceiling are the variables to adjust based on individual circumstances.

Starting Dose of Retatrutide: The Adult 2mg Initiation Phase

The phase 2 trial used 2mg as the standard adult starting dose, and that is the clinical baseline. Some protocols use 1mg for adults with a documented history of strong GI sensitivity to GLP-1 medications — particularly if prior semaglutide use caused significant nausea or vomiting — but 2mg is where most adults begin.

2mg is not an arbitrary floor. It is the lower of two starting doses the trial tested head to head: participants targeting 4mg and participants targeting 8mg were each split into a 2mg-start group and a 4mg-start group. Gastrointestinal events were dose-related and were partially mitigated by the lower start, which is why every schedule since has opened at 2mg rather than jumping straight to 4mg. The initiation phase buys tolerability, and the trial paid for that finding directly.

What Adults Can Expect at 2mg

At 2mg the effects are intentionally modest. Most adults notice:

• Mild appetite reduction starting days 2–3
• Possible light nausea, typically 4–8 hours post-injection
• Some early satiety — feeling full faster than baseline

Meaningful weight loss at 2mg is uncommon. Some adults lose 1–3 lbs in the first 4 weeks; others lose nothing. That is expected. The 2mg phase conditions the GI tract before therapeutic doses are introduced.

Inject on the same day each week. Some adults feel mildly off for 24 hours after injection, particularly in early weeks — plan injection timing to minimize interference with obligations.

Note on the semaglutide reference below: semaglutide is the generic drug sold under the brand names Wegovy for chronic weight management and Ozempic for type 2 diabetes. Both are FDA-approved products; the comparison here is about GI sensitivity history, not equivalent dosing or efficacy.

Titration Pace and the 4-Week Rule

Every dose level should be held for at least 4 weeks before escalating. This is not a guideline to push — it is the pharmacokinetic minimum for assessing whether you have reached true steady state.

How to Handle Dose Escalation if Side Effects Occur

GI symptoms persistent at 4mg (3+ days)? Hold at 4mg for an additional 2–4 weeks before moving to 8mg. There is no benefit to rushing.

Vomiting at any dose? Drop back to the previous dose. Remain there for at least 4 weeks before attempting another increase.

Nausea that is manageable but present? This is generally acceptable to continue through. The first week at a new dose is typically the worst; by week 2–3 at the same level, most adults report significant improvement.

Older adults or high-sensitivity adults: Default to 6-week holds at each level. The timeline to 12mg extends to approximately 5–6 months, which is entirely reasonable.

The 4mg Phase: First Real Clinical Signal

Week 5. Moving to 4mg. This is when retatrutide begins producing clinically meaningful effects in most adults.

The shift at 4mg is usually the most noticeable step. Adults who felt little at 2mg often report sudden satiety after partial meals. GIP receptor activation at meaningful levels improves insulin sensitivity and reduces sugar cravings specifically — a distinct effect not seen as prominently with semaglutide.

Side effects tend to spike briefly on moving from 2mg to 4mg. Nausea is most common, peaking 4–12 hours post-injection and usually settling within 24–48 hours. A small, low-fat meal before injecting can reduce nausea — fatty foods worsen gastric slowing under GLP-1 activity.

Maximum Dose in Adults: 8mg vs 12mg

Most dosing guides treat 12mg as the automatic next step after 8mg. That framing is not accurate to the clinical data.

The phase 2 data showed that the combined 8mg groups lost 22.8% of body weight at 48 weeks versus 24.2% for the 12mg group — a gap of 1.4 percentage points. At the 24-week mark the two doses were effectively tied: 17.3% at 8mg against 17.5% at 12mg. Whatever advantage 12mg carries shows up only in the second half of a year on the compound, and it is far smaller than most dosing guides imply. It is not a mandate to escalate.

8mg is a fully therapeutic adult dose. If weight loss is consistent, the compound is well tolerated, and satiety is adequate — staying at 8mg indefinitely is a rational, deliberate clinical choice, not a failure to escalate.

The case for escalating to 12mg in adults:

• Plateau at 8mg for 6+ weeks with meaningful weight still to lose
• Tolerating 8mg without significant side effects
• Goal is to maximize glucagon receptor activation for energy expenditure
• Older adults specifically should weigh tolerability burden more heavily here

The case for maintaining 8mg:

• Side effects are manageable but present at 8mg (12mg will likely increase them)
• Satisfied with the current rate of weight loss
• At or near target weight
• Age or comorbidity factors favor a lower maintenance burden

Neither position is a clinical failure. 12mg is one option, not the destination.

Phase 2 Efficacy by Dose Level

Least-squares mean percentage change in body weight. Source: Jastreboff et al., NEJM 2023, phase 2 trial NCT04881760.

Read down the 48-week column and the shape of the curve is the useful part. The jump from 1mg to 4mg is worth roughly 8 percentage points. From 4mg to 8mg, nearly 6 more. From 8mg to 12mg, 1.4. The dose-response is already flattening by the time you reach the top of the schedule, which is the arithmetic behind treating 8mg as a destination rather than a stopover.

A Note on Tirzepatide Brand Names

Tirzepatide, the dual-receptor drug retatrutide is most often compared to, is made by the same manufacturer (Eli Lilly) and is sold under two FDA-approved brand names: Zepbound for chronic weight management and Mounjaro for type 2 diabetes. If you already use one of these, note that their titration schedules and maximum doses are set by their own approved labels and are not interchangeable with the trial-based retatrutide schedule above.

How Retatrutide Dosing Differs From Semaglutide

The key reason the titration schedules differ is mechanism. Semaglutide (Wegovy) acts on a single receptor (GLP-1), while retatrutide (LY3437943) is a triple-receptor agonist hitting GLP-1, GIP, and glucagon. Activating three receptor pathways is why retatrutide uses its own stepwise 2mg to 12mg schedule rather than a semaglutide-style ramp; because no head-to-head trial has compared the two directly, this page does not claim one is more effective than the other.

Vial Size Calculations: What to Actually Draw Up

Retatrutide vials are typically sold as 5mg, 10mg, or 15mg. Draw volume depends entirely on reconstitution.

How to Calculate Your Draw Volume

Formula: Dose (mg) ÷ Concentration (mg/mL) = Volume to draw (mL)

Example: A 10mg vial reconstituted with 2mL bacteriostatic water gives a concentration of 5mg/mL.

Units listed assume a U-100 insulin syringe, on which 100 units = 1mL. A 10mg/mL concentration means 120 units = 1.2mL = 12mg.

Two practical notes on that table. A dash means the vial cannot supply that dose at all — a 5mg vial has no 8mg dose in it no matter how you reconstitute, and a 10mg vial reconstituted to 10mg/mL tops out at 10mg. And any draw over 100 units exceeds the barrel of a 1mL U-100 syringe: 160 units is two draws, 240 units is three. If your target dose keeps landing above 100 units, reconstitute with less bacteriostatic water next vial and raise the concentration instead.

For a step-by-step on reconstitution and injection technique, see: How to Inject Retatrutide.

10mg, 20mg, and Numbers That Are Not Doses

A recurring question from people using retatrutide injectables: I started at 10 — when can I go to 20? Almost every time, those numbers turn out not to be milligrams. They are one of two other things, and the difference matters enough to check before changing anything.

Units on the syringe. A U-100 insulin syringe is marked 0 to 100 units, where 100 units equals 1mL. Units measure volume, not dose. What 10 units actually delivers depends entirely on how the vial was reconstituted:

All rows assume a U-100 insulin syringe.

Two people both "at 10 units" can be four times apart in actual dose. Before you compare your dose to anyone else's, convert it: units ÷ 100 × concentration (mg/mL) = mg. At 5mg/mL, 40 units is 0.4mL, which is 2mg. Going from 10 units to 20 units doubles whatever you were taking, and the 4-week hold applies to that step exactly as it would to any other escalation.

Vial label size. Retatrutide is sold by the total milligrams in the vial — 5mg, 10mg and 15mg are the common sizes in the calculation table above. That number describes the whole vial, not a weekly dose. A 15mg vial is a container holding three 4mg doses with 3mg left over, or one 8mg dose plus most of a second. It is not a "15mg protocol."

If You Really Do Mean 10mg or 20mg Weekly

10mg weekly sits between the 8mg and 12mg arms of the phase 2 trial. It was never run as its own arm, so no efficacy or safety number is attached to it. That does not make it dangerous — it makes it unstudied. If you are already tolerating 8mg, 12mg is the step with published data behind it.

20mg weekly has never been given to a human in a published retatrutide trial. 12mg is the ceiling of the evidence, and the dose-response curve is visibly flattening before it gets there: 12mg beat 8mg by 1.4 percentage points at 48 weeks while carrying a higher gastrointestinal burden. Doubling past the top of the studied range does not extrapolate the results, because the results themselves stop at 12mg.

If you do want to run 10mg once weekly, the cleanest setup is a 15mg vial reconstituted with 1.5mL of bacteriostatic water, giving 10mg/mL. A 10mg dose is then 1.0mL — 100 units, the entire barrel of a 1mL U-100 syringe. The same vial reconstituted with 3mL gives 5mg/mL, where 10mg becomes 2.0mL and needs two full draws. Higher concentration, smaller volume, fewer draws.

Missed Dose Protocol

If You're Less Than 4 Days Late

Inject as soon as you remember. Then return to your regular weekly schedule from that new injection date. If your original day was Monday and you remember Thursday, inject Thursday. Next dose: the following Thursday.

If You're 4–7 Days Late (Close to Next Dose)

Skip the missed dose entirely. Take your next scheduled dose on your regular day. Do not double up — doubling a retatrutide dose would deliver 2–3 weeks of compound in a single injection given the half-life dynamics.

If You've Missed More Than 1 Week

Your blood levels have dropped meaningfully (the ~6-day half-life means 50% reduction every 6 days). Resuming at your current dose is generally fine if you missed only 1–2 weeks. If you have been off for 3+ weeks, consider dropping back one dose level for a week to re-establish tolerability — especially relevant at 12mg. Older adults who have been off for extended periods should apply the same conservative re-ramp logic used for initial titration.

Managing Side Effects Without Abandoning the Protocol

The most common retatrutide side effects during adult titration are GI-related: nausea, vomiting, diarrhea, constipation. They follow a predictable pattern — worst in the first 1–2 weeks at a new dose, then fading.

See our full guide on Retatrutide Side Effects for detailed management strategies.

Quick Reference: Side Effect Response

Adult Maintenance Phase: Recognizing When You're There

Maintenance starts when weight loss has slowed to 0–1 lb/week at your target dose and you have reached — or are close to — a satisfying weight. Continuing to escalate at that point does not make clinical sense.

Some adults step the dose down at maintenance — from 12mg to 8mg, or 8mg to 4mg — as appetite naturally stabilizes. This is a reasonable and documented pattern.

Signs of an appropriate adult maintenance dose:

• Appetite suppression is consistent but not uncomfortable
• Weight is stable week-to-week
• Side effects, if any, are predictable and manageable
• Eating is not a source of constant preoccupation

The phase 2 trial ran 48 weeks and showed that weight loss effects persist with continued dosing throughout that period. Weight regain following discontinuation is a real consideration with GLP-1 class medications, and retatrutide likely follows the same pattern seen with semaglutide and tirzepatide.

Adult Dosing Protocol Summary

Where to Source Retatrutide

Retatrutide is not yet FDA-approved. Clinical trials are ongoing, with Phase 3 results emerging in early 2026. If you're looking for a vetted source for peptide protocols, our recommended vendor is Synthro Lab — third-party tested, reliable concentration accuracy, and actual lab COAs on request.

For more on using retatrutide effectively, see our Retatrutide Dosage Chart for a printable protocol reference.